November 2, 2024
Contact for your business promotion or advertisement +91 62307-79476

Himachal-manufactured medicines for heart attack, blood sugar, cancer among 23 declared substandard

Himachal medicines

Shimla: As many as 23 drugs manufactured in Himachal Pradesh, including those meant to treat serious ailments like heart attacks, blood sugar and cancer, have failed to meet quality standards.

Across the country, a total of 67 samples were found substandard in recent testing by the Central Drugs Standard Control Organisation (CDSCO) and the State Drug Controller.

Of the 49 samples tested by the CDSCO, 20 failed quality checks, while three out of 18 samples tested by the State Drug Controller also did not meet the quality standards. Of the 23 drugs flagged in Himachal, 12 were produced in Solan, 10 in Sirmaur and one in Kangra.

 

Also Read: https://thenewzradar.com/himachal-cm-sukhu-seeks-financial-reward-from-centre-for-keeping-lungs-of-north-intact/

The Drug Controller has issued notices to the companies involved, revoked their manufacturing licences and directed the firms to recall all affected stock from the market.

The revelations emerged in the September drug alert, raising concerns about drug quality in the state, a leading hub of pharmaceutical production.

List of substandard drugs & manufacturers

Some prominent companies whose drugs failed quality tests include Pushkar Pharma’s Oxytocin, used in childbirth, and Martin & Brown’s Calcium Gluconate, a heart attack medication produced in Baddi. Other failed samples include pneumonia medication Ceftriaxone and infection treatment Gentamicin from G Laboratories in Paonta Sahib, and generic blood sugar medicine from Baddi-based Genericart.

 

Cancer drug Ifosfamide from Quality Pharmaceuticals in Kala Amb and blood pressure medication Torsemi from JM Labs in Solan were among those failing to meet quality standards. Pain medication Stay Happy Trypsin, produced by Trivision Healthcare in Baddi, was also flagged.

The authorities have intensified their scrutiny of the state’s pharmaceutical sector following these alarming findings.

Please Share Post
×